10.1016/j.phrs.2011.02.003.Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. (saxagliptin vs vildagliptin vs sitagliptin: HbA1c: -1.2% vs -1.3% vs -1.1%; FBG: -1.8 mmol/l vs -2.4 mmol/l vs -1.5 mmol/l; P2hBG: -3.4 mmol/l vs -3.7 mmol/l vs -3.2 mmol/l). This study compared the effectiveness and safety of vildagliptin and sitagliptin in patients with T2D and severe kidney disease. 2006, 28: 55-72. eCollection 2017 Jan-Mar. You can also search for this author in Int J Clin Pharmacol Ther. (saxagliptin vs vildagliptin vs sitagliptin: HbA1c: -1.2% vs -1.3% vs -1.1%; FBG: -1.8 mmol/l vs -2.4 mmol/l vs -1.5 mmol/l; P2hBG: -3.4 mmol/l vs -3.7 mmol/l vs -3.2 mmol/l). Pharmacol Res. Epub 2018 Mar 26.Diabetes Metab. The authors declare that they have no competing interests.MS collected the data, performed the statistical analyses, and wrote the manuscript; RN conceived of the research hypothesis and analyses, assisted in writing the manuscript, and edited the manuscript;TI, DT and KA reviewed and edited the manuscript; KU assisted in conception of the research hypothesis and reviewed and edited the manuscript. All authors read and approved the final manuscript.Below are the links to the authors’ original submitted files for images.This article is published under license to BioMed Central Ltd. 64 patients were treated with vildagliptin and 53 were treated with sitagliptin.HbA1c and FPG were tested at the beginning of the study and after 24 weeks. With vildagliptin treatment, mean amplitude of glycemic excursions was significantly improved compared with sitagliptin treatment (57.9 ± 22.2 vs. 68.9 ± 33.0 mg/dL; p=0.0045). Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily). We conducted a multicenter, prospective, open-label controlled trial in Japanese patients with type 2 diabetes. Treatment involves lowering blood glucose. 2015 Jun;41(3):244-7. doi: 10.1016/j.diabet.2014.07.004. T2D patients are more susceptible to kidney disease. Clipboard, Search History, and several other advanced features are temporarily unavailable. Diabetes Metab. Clin Ther. 2018 Sep 24;9(9):CD011798. COVID-19 is an emerging, rapidly evolving situation. Thank you, Kathleensitagliptin is FDA aprovel and vildagliptin is EU half life of sitagliptin is 12 hours and half life of vildagliptin is 2 to 3 hoursWhat do u mean by halve life? 10.1016/j.jdiacomp.2004.10.001.Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA: Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. J-STAGE, Japan Science and Technology Information Aggregator, Electronic 2011, 34: 1843-1847. This site needs JavaScript to work properly. 2017 Aug;13(2):68-72. doi: 10.17925/EE.2017.13.02.68. N Engl J Med. This site needs JavaScript to work properly. Consult your doctor if you are concerned about any of the side effects of Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.Dr. 2017 Feb 24;5(1):E152-E177. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( Now, please tell us the medical condition you’re interested in. You can also search for this author in To date, several clinical trials have compared differences in glucose fluctuation observed with dipeptidyl peptidase-4 inhibitor treatment in patients with type 2 diabetes mellitus. This study compared the effectiveness and safety of Vildagliptin improves insulin secretion and reduces plasma glucagon. Lancet. BMJ. Feel free to continue browsing. 1998, 352: 837-853.Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. 2017 Feb 27;2(2):CD009966. Reduction of daily blood glucose profile fluctuations by vildagliptin was superior to that of sitagliptin in Japanese patients with type 2 diabetes. Unable to load your delegates due to an error Examples include Free PMC article Name must be less than 100 characters 64 patients were treated with vildagliptin and 53 were treated with sitagliptin.HbA1c and FPG were tested at the beginning of the study and after 24 weeks. Want to give it a try? 49k … The reduction in systolic … 2006, 3: 153-165. Unable to load your delegates due to an error Side effects related to drug treatment were recorded. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial. There were no significant differences in BNP and PAI-1 levels between patients treated with vildagliptin and sitagliptin.Financial support for this study was provided by the Japan Diabetes Foundation.Emerging Risk factors collaboration: Diabetes mellitus, fasting glucose, and risk of cause-specific death.